Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$6.5B
171M shares
52-week range
$7.07 – $43.73
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $22.5M | $7.9M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $43.7K | $25.7M | $0 | $0 | $0 | $0 | $4.6M |
| Gross profit | $9.7M | $22.5M | −$17.9M | $0 | $0 | $0 | $0 | −$4.6M |
| Gross margin | 100.0% | 99.8% | -227.0% | — | — | — | — | — |
| R&D | $38.3M | $43.7M | $72.6M | $55.9M | $121.6M | $173.8M | $232.7M | $269.8M |
| Operating income | −$36.0M | −$32.2M | −$82.2M | −$75.6M | −$147.8M | −$208.1M | −$275.9M | −$333.4M |
| EBITDA | −$34.7M | −$30.9M | −$34.6M | −$70.3M | −$130.4M | −$188.8M | −$251.5M | −$321.3M |
| Net income | −$34.5M | −$30.3M | −$74.8M | −$72.3M | −$140.2M | −$192.4M | −$255.9M | −$328.9M |
| Net margin | -354.8% | -134.6% | -950.4% | — | — | — | — | — |
| EPS (diluted) | -5.55 | -3.97 | -6.00 | -1.85 | -2.26 | -2.42 | -2.46 | -2.55 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-2.25 | $-2.68–$-2.04 | 9 |
| 2027 | $345M | $-0.78 | $-1.45–$0.21 | 8 |
| 2028 | $730M | $0.77 | $-0.35–$2.98 | 10 |
| 2029 | $1.3B | $2.73 | $0.41–$6.73 | 4 |
Forward consensus · source: Financial Modeling Prep
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
www.cogentbio.comNo one on the platform currently holds COGT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 706,268 | $27.2M |
| Execution date | Ratio |
|---|---|
| 2020-11-09 | 1-for-4reverse |
No one on the platform has traded COGT yet.
| $1.8B |
| — |
| IBRXImmunityBio, Inc. | $8.71 | +11.81% | $9.1B | — |
| LQDALiquidia Corporation | $78.17 | +1.63% | $7.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$COGT Bio name that is trying to breakout of massive consolidation. Monthly, Weekly, Daily flag.
View on StockTwits ↗$COGT over the downtrend resistance line. Needs to hold till close… and the biotech sector continues to be strong, while the overall markets are weak $IBB $XBI
View on StockTwits ↗$COGT Cogent Biosciences Inc. (COGT) is turning heads with a 68.25% stock upside estimate, a $5.55 billion market cap, and a precision oncology pipeline targeting rare blood cancers. With fresh CGT1145 data and strong interest from hedge funds, this healthcare stock may be one of the most intriguing biotech names to watch. https://biotechhealthx.com/biotech-news/heres-why-cogent-biosciences-cogt-is-getting-attention-from-biotech-investors/
View on StockTwits ↗$COGT $INSM $LEGN $PCVX $SMMT These 5 healthcare stocks are drawing attention from Wall Street analysts because of strong stock upside, clinical trial updates, market expansion, biotech innovation, and major healthcare growth catalysts. https://biotechhealthx.com/biotech-news/top-5-healthcare-stocks-that-could-turn-a-1000-investment-into-something-bigger/
View on StockTwits ↗@Blaze1911 $COGT is another that had big volume than normal (Thursday); may want to keep track of that one as well. Also with an ER around the corner. I miss plenty of things myself because I own (and need to watch) a long list of stocks (watchlist). But I do manage to catch some of them occasionally and I share what I find. Good luck with $CAPR if you decide to go in.
View on StockTwits ↗$APGE news is out that $ABBV is buying APGE for a big premium. APGE was one of 3 buyout targets (other 2 were $COGT & $INBX) mentioned by the biotech analyst on CNBC Fast Money last night..
View on StockTwits ↗$COGT Volume of 4.9 Million with avg around 2.4 Million. ER coming up on 04Aug. Keep it on your radar.
View on StockTwits ↗$COGT Cogent Biosciences (Nasdaq: $COGT) Deep Dive: Bezuclastinib, Three FDA Paths, and the EHA APEX Catalyst https://www.merlintrader.com/cogent-biosciences-june2026-deepdive/
View on StockTwits ↗$COGT Share Price: $31.97 Contract Selected: Nov 20, 2026 $33.0 Calls Buy Zone: $2.63 – $3.26 Target Zone: $4.53 – $5.54 Potential Upside: 62% ROI Time to Expiration: 163 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$COGT let me try this again. EHA cheat sheet
View on StockTwits ↗$COGT created a little cheat sheet for the EHA conference, enjoy.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.